Treatment of Dermal Fibroblasts with GPI-Anchored Human TIMP-1 Protein Moderates Processes Linked to Scar Formation  by Djafarzadeh, Roghieh et al.
Treatment of Dermal Fibroblasts with GPI-Anchored
Human TIMP-1 Protein Moderates Processes Linked
to Scar Formation
Roghieh Djafarzadeh1, Susan Notohamiprodjo1, Nicole Rieth1, Monika Hofstetter1, Elfriede Noessner2 and
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Tissue inhibitors of metalloproteinases exhibit diverse physiological/biological functions including moderation of
the proteolytic processing of growth factors and turnover of extracellular matrix. These various biological
activities are linked in part to the stoichiometry of tissue inhibitor of metalloprotein/matrix metalloprotein (TIMP/
MMP)/surface protein interactions. TIMP-1, a secreted protein, can be detected on the cell surface only through
its interaction with surface-bound proteins. Proteins anchored by glycosylphosphatidylinositol (GPI), when
purified and added to cells or tissues, are efficiently incorporated into their surface membranes. A GPI anchor
was fused to TIMP-1 to focus defined concentrations of the inhibitory protein independently on the surface of
primary dermal fibroblast cells. Exogenously added recombinant TIMP-1-GPI effectively inserted into the cell
membrane of fibroblasts blocked the secretion of MMPs and markedly altered the stoichiometry of MMP
association with the cell surface. TIMP-1-GPI treatment resulted in inhibition of fibroblast-reduced proliferation,
and transiently reduced expression of fibrosis-associated genes. These effects were dose dependent. Treated
cells also showed a more proapoptotic phenotype based on apoptotic assays and western blot analysis for
apoptosis-associated protein expression. GPI-anchored TIMP-1 may represent a more effective version of the
protein for use in therapeutic approaches to help control fibrosis and scar formation.
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INTRODUCTION
During wound healing, fibroblasts regulate the formation and
contraction of granulation tissue. They are recruited to the site
of the wound where they proliferate and undergo activation to
myofibroblasts. During normal wound healing, the myofibro-
blasts eventually undergo apoptosis. In pathological situations,
sustained fibroblast activation and reduced apoptosis can lead
to myofibroblast overproliferation, excessive extracellular
matrix production (ECM), overcontraction, and eventually
hypertrophic or keloid scar formation (Clark, 1993; Schaffer
et al., 1997; Fattman, 2008).
In tissue remodeling, the production of ECM is generally
counterbalanced by its turnover. The catabolism is mediated
by various enzyme families that include the matrix metallo-
proteinases (MMPs) (Bonewald, 1999; Crosby and Waters,
2010; Mirastschijski et al., 2010). In humans, there are 23
MMPs subgrouped by their substrate specificity and cellular
localization. They include the collagenases, gelatinases,
stromelysins, and membrane-type MMPs (Sternlicht and
Werb, 2001; Morrison et al., 2009; Fanjul-Fernandez et al.,
2010). The catalytic activity of MMPs is generally low in
normal tissue, but are increased during inflammation and
wound repair (Overall and Lopez-Otin, 2002). Importantly,
these enzymes do more than metabolize ECM. Many
membrane-bound cytokines, receptors, and adhesion
molecules are also processed, or released from the cell
surface, by the action of MMPs. Thus, this enzyme family
can be seen as controlling diverse aspects of tissue homeo-
stasis and wound repair, and therefore represents a potential
target for therapeutic intervention in some pathologic settings.
Although MMP expression can be controlled transcription-
ally by cytokines and growth factors, their catalytic activity
is also regulated by four endogenous inhibitors, the tissue
inhibitors of metalloproteinases (TIMP-1, TIMP-2, TIMP-3 and
TIMP-4) (Brew et al., 2000; Overall and Lopez-Otin, 2002).
The balance between MMP/TIMP expression is essential for
the regulation of tissue homeostasis and is linked to various
pathogenic processes (Brew et al., 2000; Ra and Parks, 2007;
Mirastschijski et al., 2010).
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The bioactivity of TIMP-1 can be altered by changing its
subcellular distribution (Djafarzadeh et al., 2004, 2006, 2009,
2012; Raggi et al., 2009). Human TIMP-1 protein was
modified by fusion to a glycosylphosphatidylinositol (GPI)
anchor. GPI-anchored proteins can be efficiently transferred
from one cell to another through a process called cell painting
(Medof et al., 1996; Djafarzadeh et al., 2004). Recombinant
TIMP-1-GPI is efficiently incorporated into cell membranes
where it results in a shift in the proteolytic microenvironment
at the cell surface. This can result in enhanced and new
cellular behavior (Djafarzadeh et al., 2004, 2006, 2009, 2012;
Raggi et al., 2009).
The effect of GPI-anchored TIMP-1 treatment on dermal
fibroblast biology was evaluated. Application of TIMP-1-GPI
led to markedly reduced matrix gene expression and fibroblast
proliferation, and rendered cells more sensitive to apoptosis.
Treatment with TIMP-1-GPI may show efficacy for the
suppression of scar formation.
RESULTS
Exogenously added TIMP-1-GPI incorporates into surface
membranes of primary dermal fibroblasts
GPI-anchored TIMP-1 protein was generated and isolated
as previously described (Djafarzadeh et al., 2004). The
incorporation of purified TIMP-1-GPI protein into the surface
membrane of primary dermal fibroblasts was demonstrated by
incubation of purified 14 ng ml1 TIMP-1-GPI or recombinant
human TIMP-1 (rhTIMP-1) control protein for 30 minutes at
37 1C (see Materials and Methods). Surface-associated TIMP-1
protein was measured using a human TIMP-1-specific anti-
body and FACS (Figure 1a). Incubation with control human
recombinant TIMP-1 or vehicle did not result in a fluorescence
shift; however, addition of GPI-anchored TIMP-1 resulted in
a strong surface signal for TIMP-1. The necessity of the GPI
anchor was verified by digestion of TIMP-1-GPI-treated
fibroblasts with phospholipase C (PLC) (120 ng ml1), which
specifically cleaves GPI anchors. PLC treatment led to a loss of
TIMP-1 signal measured by FACS. The efficiency of incorpora-
tion was determined by measuring the resultant free TIMP-1
protein left in the supernatant after incorporation by TIMP-1-
specific ELISA. As previously reported (Djafarzadeh et al.,
2006), the efficiency of incorporation was generally between
30 and 60% of input protein (data not shown).
The effect of surface-bound TIMP-1 on the secretion of
MMP-2 and MMP-9 by fibroblasts was tested using gelatinase
zymography (Djafarzadeh et al., 2006) (Figure 1b). Recombi-
nant hTIMP-1 protein added at 14 ng ml1 had limited effects
on the secretion of MMP-2 or MMP-9. In contrast, when
added at a concentration of 7 or 14 ng ml1, TIMP-1-GPI led
to a reduction in the secretion of both proMMP-2 and
proMMP-9. Heat-denatured TIMP-1-GPI (TIMP-1-GPI) did
not lead to reduced secretion of the gelatinases. This reduction
in secretion was then quantified using MMP-2- and MMP-9-
specific ELISAs performed on growth media from the treated
cells (Figure 1c).
To establish whether the reduction in gelatinase secretion
was permanent, the GPI anchor was again cleaved from the
TIMP-1-GPI-treated cells using PLC (120 ng ml1) 24 hours
after treatment. After an additional 24 hours, the cell culture
supernatants were assayed for the presence of MMP-2 and
MMP-9 by gelatinase zymography. The results show that
following GPI digestion (lane 7) the fibroblast cells re-secrete
the two gelatinase enzymes at approximately the same
level seen in the buffer and rhTIMP-1 controls (lane 4)
(Figure 1d).
Treatment with TIMP-1-GPI leads to an increase in the surface
expression of MMPs
TIMP-1 binds to all active forms of MMPs with the exception
of MMP-14. On the basis of the reduced secretion of the
gelatinases observed, TIMP-1-GPI treatment may lead to a
sequestering of MMPs on the cell surface (Djafarzadeh et al.,
2006). Following incubation of the fibroblasts with 14 ng ml 1
of TIMP-1-GPI protein for 24 hours, FACS analyses was
performed using MMP-1-, MMP-2-, MMP-9-, and MMP-13-
specific antibodies, which showed an increase in mean
channel fluorescence for each MMP studied (Figure 2) (Brew
et al., 2000). To further verify that this was not a nonspecific
effect, the surface expression of collagen and tumor necrosis
factor binding protein 2 was evaluated in parallel. Surface
expression of these molecules was not effected by TIMP-1-GPI
treatment (Figure 2).
GPI-anchored TIMP-1 suppresses serum and tumor necrosis
factor-a (TNF-a) induced fibroblast proliferation
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
stainings were performed to assess the effect of TIMP-1-GPI
on the proliferation of activated dermal fibroblasts. Serum is
a potent stimulator of fibroblast proliferation. TNF-a at low
concentrations can also stimulate fibroblast proliferation
(Hetzel et al., 2005). The effect of TIMP-1-GPI on proli-
feration of primary dermal fibroblast cells was determined
in response to serum, and in combination with different
concentrations of TNF-a (Figure 3). TIMP-1-GPI-treated fibro-
blasts showed a dose-dependent reduction in proliferation
(at 48 hours) to low concentrations of TNF-a (400 pg ml1)
or serum stimulation (Figure 3). Heat-denatured TIMP-1-GPI
or rhTIMP-1 had no effect. Higher TNF-a reduced serum-
stimulated proliferation and TIMP-1-GPI completely abolished
proliferation of TNF-a-stimulated fibroblasts.
TIMP-1-GPI leads to increased apoptosis of dermal fibroblast
cells and shifts the expression of proapoptic and antiapoptotic
proteins
Fibroblast apoptosis is crucial to the resolution of fibrosis
(Gabbiani, 2003; Fattman, 2008). Reduced fibroblast apop-
tosis is associated with pathological scar formation (Fattman,
2008). A FACS-based assay using Annexin V/7-aminoactio-
mycin D staining was used to assess the effect of TIMP-1-GPI
treatment on the apoptosis of fibroblasts. TIMP-1-GPI
treatment, but not rhTIMP-1, was found to increase the level
of apoptosis in dermal fibroblasts (Figure 4a).
The cellular mechanisms involved in fibroblast apoptosis
are not well understood, but are linked to the expression of the
Bcl-2 family of proteins (Gabbiani, 2003). This family includes
members that can suppress (Bcl-2 and Survivin) or increase
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(Bax and Apaf-1) the level of apoptosis. The balance between
pro and antiapoptotic Bcl-2 proteins helps dictate the ability of
cells to undergo apoptosis.
Bcl-2, Bax, Survivin, and Apaf-1 protein expression was
analyzed following treatment. Dermal fibroblasts were pre-
incubated with TIMP-1-GPI or rhTIMP-1 for 24 hours. Proteins
were then extracted from whole-cell lysates and western
blot analysis was performed (see Materials and Methods)
(Figure 4b). TIMP-1-GPI led to a reduction in cellular levels
of antiapoptotic Bcl-2 and Survivin, but showed a corres-
ponding increase in levels of the proapoptotic Apaf-1 and Bax
proteins, potentially explaining the proapoptotic effect of
TIMP-1-GPI treatment seen.
TIMP-1-GPI treatment transiently reduces messenger RNA
(mRNA) expression of fibrosis-associated genes
A quantitative assessment of the mRNA expression of a select
group of genes linked to fibrosis and components of ECM was
carried out using TaqMan reverse transcriptase PCR (RT-PCR)
analysis. Primary dermal fibroblasts were left untreated, or
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Figure 1. Tissue inhibitor of metalloproteinases-1-glycosylphosphatidylinositol (TIMP-1-GPI) is efficiently reincorporated into the surface membranes of
fibroblasts and reduces the secretion of matrix metalloprotein (MMP)-2 and MMP-9. (a) Purified TIMP-1-GPI or control recombinant human (rh) TIMP-1
was added to primary dermal fibroblasts and TIMP-1 detected by FACS analysis. Gray histograms represent isotype controls and solid-line histograms represent
TIMP-1 antibody staining. To demonstrate GPI linkage, treated cells were incubated with 120 ng ml1 PLC and then subjected to FACS analysis. (b) TIMP-1-GPI
treatment reduced MMP-2 and MMP-9 release into the growth media as seen by gelatine zymography. (c) ELISA was used to quantify MMP-2 and MMP-9
proteins. (d) The reduced gelatinase secretion seen with TIMP-1-GPI treatment recovered following PLC treatment. Fibroblasts were pretreated with vehicle,
rhTIMP-1, or TIMP-1-GPI for 24 hours, and then treated by phospholipase C (PLC) digestion. After an additional 24 hours, the cell culture supernatants were
assayed by gelatinase zymography. rhTIMP-1, recombinant human TIMP-1.
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treated with 7 ng ml1 TIMP-1-GPI, 14 ng ml1 TIMP-1-GPI,
14 ng ml1 of heat-denatured TIMP-1-GPI, or 14 ng ml1 of
rhTIMP-1. After 30 minutes, the cells were washed with
medium and then stimulated with increasing concentrations
of serum (0, 1, 5, and 10% fetal calf serum), with or without
the presence of 10 ng ml1 TNF-a. After 48 hours, mRNA was
isolated and subjected to analysis using TaqMan RT-PCR. The
genes analyzed were collagen 1A1, collagen 4A2, fibronectin,
collagen 16A1, connective tissue growth factor, and trans-
forming growth factor beta 1 (tgf-b1). In each instance, a dose-
dependent increase in mRNA expression was seen in response
to serum stimulation (Figure 5a–f). In some instances, TNF-a at
10 ng ml1 costimulation led to an increased level of mRNA
expression over that seen with serum stimulation alone. TIMP-
1-GPI treatment was found to suppress the induced expression
of each of the genes.
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Figure 2. Tissue inhibitor of metalloproteinases-1-glycosylphosphatidylinositol (TIMP-1-GPI) treatment led to increased surface expression of matrix
metalloproteinases (MMPs). Following incubation of primary dermal fibroblasts with 14 ng ml of purified recombinant human (rh) TIMP-1-GPI protein for
24 hours, FACS analyses using MMP-1-, MMP-2-, MMP-9-, and MMP-13-specific antibodies were performed. Shown are increased mean channel fluorescence
(MCF) signals for TIMP-1 after cell treatment with TIMP-GPI, as well as increased fluorescence of MMP-1, MMP-2, MMP-9, and MMP-13. Gray histograms
represent isotype controls, and solid-line histograms represent respective antibody stainings. TBP is tumor necrosis factor binding protein II. Shown are
representative histograms of repeated experiments with similar results. rhTIMP-1, recombinant human TIMP-1.
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To determine whether the effects of TIMP-1-GPI on steady-
state mRNA expression were reversible, in a parallel set of
experiments, 24 hours after the fibroblasts had been treated
with 14 ng ml1 TIMP-1-GPI, 14 ng ml1 of heat-treated
TIMP-1-GPI, or 14 ng ml1 of rhTIMP-1 as described above,
the cells were subjected to PLC digestion (120 ng ml1) and
placed back into culture for an additional 24 hours; RNA was
then isolated and tested for the level of expression of the
various genes. The results demonstrated that the TIMP-1-GPI
effects are reversible and that the overall process does not
appear to be overly toxic to primary dermal fibroblast cells
(Figure 5a–f).
DISCUSSION
By linking a GPI anchor to TIMP-1, an agent was generated
that moderates the response of primary dermal fibroblasts to
stimulation by TNF-a or serum. Treated cells showed a shift
toward apoptosis, reduced proliferation, and suppressed the
expression of matrix components.
TIMPs and MMPs are key components in the formation,
remodeling, and degradation of matrix proteins (Gabbiani,
2003; Hetzel et al., 2005; Mirastschijski et al., 2010).
A balance between ECM deposition and protease activity
needs to be optimally regulated during wound healing. In skin,
tissue repair involves the proliferation of fibroblasts, which
migrate into the wound, differentiate into myofibroblasts,
produce, and contract the ECM, leading to wound
closure and restoration of tissue function (Singer and Clark,
1999; Gabbiani, 2003; Denton and Abraham, 2004; Leask
and Abraham, 2004). This is accompanied by apoptosis of
fibroblasts/myofibroblasts within the wound (Gabbiani, 2003).
Where the balance between the breakdown and deposition of
ECM is disturbed, or when apoptosis is inefficient, abnormal
wound healing may result in excessive scarring or keloid
scarring (Gabbiani, 2003). The present study suggests that
GPI-anchored TIMP-1 may effectively control, alter, inhibit, or
prevent undesirable processes associated with excessive
scaring.
The fusion of a GPI anchor to human TIMP-1 protein yields
a protein with pronounced effects on fibroblasts. TIMP-1-GPI
treatment resulted in a sequestering of MMPs on the surface of
cells and reduced expression of matrix-associated protein
genes. The effects of treatment were reversible, as cleavage
of the GPI anchor using PLC, resulting in the release of TIMP-1
from the surface, led to re-secretion of the gelatinase MMPs
and the re-expression of profibrotic genes.
The increased expression of fibronectin, collagen 1A1,
collagen 4A2, and 16A1 is linked to fibroproliferative
scarring (Zhu et al., 2008). Serum- and TNF-a-induced
mRNA expression of these genes by dermal fibroblasts
was reduced in a dose-dependent manner in response to
TIMP-1-GPI treatment. The cytokines connective tissue
growth factor and TGF-b1 also have important roles in
wound healing (Singer and Clark, 1999; Leask and
Abraham, 2004; Margadant and Sonnenberg, 2010). TIMP-1-
GPI treatment reduced the mRNA expression of both
cytokines. In addition, TIMP-1-GPI treatment also inhibited
the steady-state level of MMP-2 and MMP-9, suggesting
that, in addition to sequestering the proteins on the cell
surface, TIMP-1-GPI also reduced transcription of the genes
(Supplementary Figure S1 online).
The observation that increased concentrations of TIMP-1
could lead to a reduction in fibrosis seems at first glance
counter-intuitive. A reduction in MMP activity by increased
levels of TIMP-1 at the cell surface should result in a more
pronounced accumulation of matrix components because of a
blockade in their catabolism. The effects seen may be linked
to the observed reduced expression of tgf-b1 mRNA and
protein resulting from treatment (Djafarzadeh et al., 2012).
TGF-b1 is known to stimulate the proliferation of fibroblasts
(Moses et al., 1990; Verrecchia et al., 2001; Leask and
Abraham, 2004). Recent studies by our group have shown
that TIMP-1-GPI treatment can block the processing of latent
TGF-b1 to its active form in other cell types (Djafarzadeh
et al., 2012; Djafarzadeh et al., unpublished results). This
effect may underlie, in part, the generally positive effects of
TIMP-1-GPI treatment seen in in vitro and in vivo models of
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Figure 3. Tissue inhibitor of metalloproteinases-1-glycosylphosphatidyl-
inositol (TIMP-1-GPI) treatment suppresses serum and tumor necrosis
factor-a (TNF-a)-induced fibroblast proliferation. 3-(4,5-Dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide assays were performed to assess the effect of
TIMP-1 surface engineering on the proliferation of fibroblasts. Serum and/or
TNF-a were used to stimulate proliferation. Fibroblasts treated with 7 or
14ngml1 TIMP-1-GPI showed a reduction to serum (0, 1, 5, or 10%)
and/or TNF-a (0.4, 1, or 10ngml 1) induced proliferation after 48hours
of treatment. Control recombinant human (rh) TIMP-1 or heat-denatured
TIMP-1-GPI at 14ngml 1 did not strongly influence proliferation of the cells.
dTIMP, denatured tissue inhibitor of metalloprotein-1; FCS, fetal calf serum;
rhTIMP-1, recombinant human TIMP-1.
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wound healing. As many autocrine and paracrine growth
factors also undergo proteolytic processing (Leask and
Abraham, 2004; Broughton et al., 2006), TIMP-1-GPI may
have additional effects on fibroblast biology. Finally, treatment
brought about a shift in the intracellular levels of
Bcl-2 proteins toward a more proapoptotic posture in the
dermal fibroblasts. Thus, TIMP-1-GPI treatment may posi-
tively influence a series of events linked to pathologic scar
formation, including the dysregulation of apoptosis asso-
ciated in wound-healing abnormalities. Topical application
of TIMP-1-GPI may find efficacy in specific wound healing
situations.
MATERIALS AND METHODS
Cellular reagents and tissue culture
Primary human dermal fibroblast cells NHDF-c (PromoCell,
Heidelberg, Germany, No. C-12300) were cultured in Dulbecco’s
MEM with Glutamax-1 (GIBCO BRL, Life Technologies GmbH,
Eggenstein, Germany, No. 21885-025) supplemented with 10%
heat-inactivated fetal calf serum. All experiments adhered to the
Declaration of Helsinki Principles.
Fluorescence-activated cell scanning analysis
Human TIMP-1, MMP-1, MMP-2, MMP-9, MMP-13, and MMP-14
were identified on the cell surface of primary fibroblasts by FACS
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Figure 4. Treatment of fibroblasts with tissue inhibitor of metalloproteinases-1-glycosylphosphatidylinositol (TIMP-1-GPI) renders the cells more sensitive
to apoptosis. Fibroblast cells were untreated or treated with vehicle, 12 ng ml1 TIMP-1-GPI, or recombinant human (rh) TIMP-1. (a) Binding of annexin V-FITC
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or rhTIMP-1 was analyzed by western blot analysis. FL, fluorescence channel; rhTIMP-1, recombinant human TIMP-1.
Figure 5. Tissue inhibitor of metalloproteinases-1-glycosylphosphatidylinositol (TIMP-1-GPI) treatment transiently moderates the steady-state expression of
fibrosis-associated genes. Primary dermal fibroblasts were treated with 7 ng ml 1 TIMP-1-GPI, 14 ng ml1 TIMP-1-GPI, 14 ng ml 1 of heat-treated TIMP-1-GPI,
or 14 ng ml1 of recombinant human (rh) TIMP-1 and then stimulated with serum (0, 1, 5 and 10% FCS), with or without the presence of 10 ng ml1 tumor
necrosis factor-a (TNF-a). After 48 hours, messenger RNA was isolated and subjected to analysis using TaqMan reverse transcriptase PCR (RT-PCR). In parallel,
fibroblasts treated for 24 hours were subjected to phospholipase C (PLC) digestion (120 ng ml 1) and placed back into culture for an additional 24 hours. The genes
analyzed were (a) collagen 1A1, (b) collagen 4A2, (c) fibronectin, (d) collagen 16A1, (e) connective tissue growth factor, and (f) transforming growth factor
beta 1 (TGF-b). FCS, fetal calf serum; rhTIMP-1, recombinant human TIMP-1; rRNA, ribosomal RNA.
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analysis. Cells at 80% confluency were washed with serum-free
medium and incubated with 14 ng ml 1 TIMP-1-GPI or rhTIMP-1 for
2 hours at 37 1C. The cells were washed again and incubated in
serum-free medium overnight. Cells were detached using Biotase
(Biochrom A, Berlin, Germany, No. L2193) and incubated for
60 minutes on ice with TIMP-1 antibody (No. IM32L), MMP-1
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antibody (No. IM35L-100 UG), MMP-13 antibody (No. IM44L) (all
from Calbiochem, Merck Darmstadt, Germany), MMP-2 antibody
(No. IM 51L), MMP-9 antibody (No. IM 61-100 UG) (from Oncogene,
Bad Soden, Germany), anti-hFibronectin (DakoCytomation A/S,
Glostrup, Denmark, No. A0245), or isotype control IgG1k (Sigma-
Aldrich, Taufkirchen, Germany, No. M9269). The cells were washed
with 1 phosphate buffered saline (PBS) and incubated with an
FITC-conjugated human anti-mouse (Dako A/S, Glostrup, Denmark,
No. F0313) IgG for 45 minutes on ice. The cells were washed with
PBS and analyzed via FACS (FACS Calibur, Becton, Dickinson and
Company, San Jose, CA) using the CellQuest analysis software (FACS).
Purification of TIMP-1-GPI protein
The TIMP-1-GPI protein was produced and purified as previously
described (Djafarzadeh et al., 2004).
Incorporation of TIMP-1-GPI into cell membranes and
enzymatic cleavage of the GPI anchor
Fibroblasts (5 105 cells ml 1) were incubated for 1 hour with
14 ng ml 1 of purified hTIMP-1-GPI at 37 1C/5% CO2. The cells
were then harvested and washed once with cold PBS and analyzed by
FACS using human TIMP-1-specific monoclonal antibodies (see
above). For GPI-anchor digestion, TIMP-1-GPI-anchored fibroblast
cells were treated with 120 ng ml 1 phosphatidylinositol-specific PLC
(Sigma-Aldrich, No. 661-9) in serum-free medium for 30 minutes at
37 1C. The cells were washed three times with cold PBS and analyzed
by FACS.
Zymography
Dermal fibroblast cells were cultured in 24-well plate (5 104 cells in
each well). The medium was changed after 24 hours with serum-free
medium containing the TIMP-1-GPI and rhTIMP-1 and incubated
for 1 hour. The cells were then washed once with medium,
and incubated for 24, 48, and 72 hours in 1 ml of serum-free medium.
Cell supernatants were analyzed by gelatinase zymography
using 10% SDS-polyacrylamide gels (Invitrogen, Groningen,
The Netherlands, No. EC61755BOX) containing 0.1% gelatin, and
cell supernatants were loaded in a 1:2 dilution with SDS sample
buffer (Invitrogen, No. LC2676). Recombinant MMP-9 enzyme
(Amersham Biosciences, Uppsala, Sweden, No. RPN2634) was used
as positive control. After electrophoresis at 130 Volts for 1.5 hours, the
gels were renatured for 30 minutes and subsequently developed
for 96 hours at 37 1C. Gels were stained with Coomassie blue and
destained with deionized water.
Proliferation
Primary dermal fibroblasts at a density of 5 103 were cultured in
96-well microtiter plates for 24 hours to yield firmly attached and
stably growing cells. After discarding supernatants, 50ml of medium
containing native TIMP-1-GPI, denatured TIMP-1-GPI (1 hour at
90 1C), vehicle, or rhTIMP-1 were added and the cells were incubated
from 24 to 72 hours. Next, 50ml of 1 mg ml 1 solution of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added.
After 3 hours of incubation at 37 1C, formazan crystals were dissolved
by the addition of 100ml isopropanol and 0.04 N HCl. Absorbance
was measured at 570 nm using GENios plus TECAN ELISA reader
(Ma¨nnedorf, Switzerland). For each experiment, at least six wells
were analyzed per experimental condition and time point.
Annexin V detection of apoptosis
Detection and quantification of apoptotic versus necrotic cells
at the single-cell level was performed using Annexin-V-FLUOS
staining kit (Becton, Dickinson and Company, Heidelberg, Germany,
No. 556547). Normal human dermal fibroblast cells from an
adult donor (PromoCell, No. C-12302) were seeded at a density of
1 106 cells per flask into 25-cm2 flasks and allowed to attach
overnight. The flasks were then rinsed once with serum-free medium
and 1 ml of serum-fibroblast growth medium (PromoCell, No.
C-23010) was added, followed by 12 ng ml 1 of TIMP-1-GPI or
rhTIMP-1. Cells were incubated overnight at 37 1C/5% CO2. The cells
were washed with PBS, pelleted, and resuspended in staining solution
(Annexin-V-fluorescein labeling reagent and 50mg ml 1 7-Aminoac-
tiomycin D (Sigma-Aldrich, No. A9400)) for 15 minutes at room
temperature. The cells were then analyzed by flow cytometry.
Western blot analysis
The fibroblasts were washed three times with cold PBS and detached
with 1.5 mM EDTA. The cells were rotated for 1 hour at 4 1C with
hypertonic lysis buffer (5 mM Tris, 2 mM MgCl, 0.1 mM EDTA, 1 mM
PMSF (Roche, Basel, Switzerland, No. 236608), 2mg ml 1 Aprotinin
(Roche, No. 1583794), 2mg ml 1 leupeptin (Sigma, Taufkirchen,
Germany, No. L2884), 1mg ml 1 pepstatin A (Roche, Basel,
Switzerland, No.1524488), pH 7.4). Cell membranes were isolated
with extraction buffer (100 mM NaCl, 1% Triton X-100, 10 mM Tris,
5 mM EDTA, 1 mM PMSF, 2mg ml 1 aprotinin, 2mg ml 1 leupeptin,
1mg ml 1 pepstatin A, pH 7.4) and were rotated for 1 hour at 4 1C,
followed by centrifugation at 11,000g for 20 minutes at 4 1C. The
supernatant was used for further western blot tests.
Whole-cell lysates containing 40mg of protein were denatured by
boiling for 5 minutes in SDS sample buffer and then loaded and
separated by 4–20% SDS-PAGE. After electrophoresis, proteins were
transferred to polyvinylidene fluoride membranes (Invitrogen, No.
LC2002) and tested. Western blot analysis was used for the detection
of BCL-2 (ALX-804-225, Axxora, LLC Farmingdale, NY), BAX (ANC-
357-040, Axxora), APAF-1 (AAP-300, Assay Designs (Ann Arbor, MI)),
Survivin, (MAB886, R&D Systems, Minneapolis, MN), and b-Actin
(Acris, Hiddenhausen, Germany, No. ab8227) using a commercial
western blot analysis kit, Chemiluminescent Immunodetection System
(Invitrogen).
RT-PCR analyses
Total fibroblast RNA was isolated for standardized quantitative
RT-PCR by using the RNeasy MiniKit 50 (Quiagen, Hilden, Germany,
No. 74104). In brief, 2mg of total RNA from cultured fibroblast cells
was used for random primed reverse transcription using a modified
MMLV reverse transcriptase (Superscript II, Life Technologies,
Karlsruhe, Germany) for 1 hour at 40 1C. Real-time RT-PCR was
performed on a TaqMan 7000 Sequence Detection System (Applied
Biosystems, Warrington, UK) using heat-activated TaqDNA polymer-
ase (Amplitaq Gold, PE Biosystems, Weiterstadt, Germany). After
2 minutes at 50 1C and 10 minutes at 95 1C, the samples were cycled
45 times at 95 1C for 15 seconds and 60 1C for 60 seconds. PCR
products were labeled by internal fluorescence probes (MMP-9 and
b-Actin) or with intercalating DNA dyes (MMP-2, Applied Biosystems).
mRNA expression for each signal was calculated following the DCt
procedure (Cohen et al., 2001). The amplification efficiency was
defined as 1, as all compared analyses were performed during the
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same run including the control dilution series. Glyceraldehyde-3-
phosphate dehydrogenase and b-Actin were used as reference genes.
Commercial TaqMan reagents were used for collagen 16A1
(No. HS00156876-ml), collagen 1A1 (No. HS00156876-m1), tgf-b
(No. HS99999918-m1), connective tissue growth factor (No.
HS00170014-m1), fibronectin (No. HS00277509-m1), and b-actin
(No. 4333762F). MMP-2 and MMP-9 primers were obtained from
Applied Biosystems.
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